Der var også en tendens mod højere hyppighed af HBeAg tab (35% vs 29%) og serokonvertering (30% vs 25%) for telbivudin.
A trend towards higher rates of HBeAg loss (35% vs 29%) and seroconversion (30% vs 25%) was also observed for telbivudine.